Haemophilus influenzae type b (Hib) vaccine

BIOLOGICAL3 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, Novartis Vaccines

Conditions

Haemophilus Influenzae Type b (Hib) InfectionMeningitisMeningococcemia

Phase 2

Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

CompletedNCT00771849

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcemia

Start: 2003-08-31End: 2004-05-31Updated: 2016-04-14

Phase 3

Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China

CompletedNCT01044316

Novartis VaccinesHaemophilus Influenzae Type b (Hib) Infection

Start: 2010-04-30End: 2010-12-31Updated: 2011-12-30

Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants

CompletedNCT01226953

Novartis VaccinesHaemophilus Influenzae Type b (Hib) Infection

Start: 2010-10-31End: 2011-03-31Updated: 2011-12-30

Related Papers

Assessment of immunogenicity and safety following primary and booster immunisation with a CRM<sub>197</sub>-conjugated<i>Haemophilus influenzae</i>type b vaccine in healthy Chinese infants

International Journal of Clinical Practice2013-08-223 citations